Patents by Inventor Henry Lamparski

Henry Lamparski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240035073
    Abstract: Disclosed herein are methods for detecting a target protein in a sample and methods for detecting a target protein and a target nucleic acid in a sample. Kits for carrying out the methods are also disclosed.
    Type: Application
    Filed: July 27, 2023
    Publication date: February 1, 2024
    Inventors: Xiao-Jun Ma, Bingqing Zhang, Henry Lamparski, Courtney Todorov, Lydia Hernandez, Vasudha Murlidhar, Haiyan Wu, HaYeun Ji, Emerald Doolittle, Maithreyan Srinivasan, Li-chong Wang
  • Publication number: 20060165658
    Abstract: Adenovirus vectors replication specific for cells expressing ?-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Application
    Filed: November 7, 2005
    Publication date: July 27, 2006
    Inventors: Andrew Little, Henry Lamparski, Daniel Henderson, Eric Schuur
  • Publication number: 20050042272
    Abstract: The present invention relates to compositions comprising vesicles released from activated T lymphocytes, as well as to methods for their production and uses. Said vesicles contain a set of bioactive molecules which confer remarkable properties, such as antigen recognition, antigen presentation and other regulatory and effector functions. This invention also relates to methods for transferring or delivering antigenic molecules (e.g., peptides, peptide/MHC complexes, TCR or subunit thereof, etc.) to antigen presenting cells (APCs) using said vesicles, to induce specific immune responses, particularly specific CTL responses. The invention further relates to methods of delivering molecules selectively or specifically to target cells using said vesicles.
    Type: Application
    Filed: March 13, 2003
    Publication date: February 24, 2005
    Inventors: Yafei Hou, Du-Hwei Hsu, Anita Mehta-Damani, Henry Lamparski, Redro Paz, Jean-Bernard Le Pecq
  • Publication number: 20040241176
    Abstract: The present invention relates to methods of preparing biological material, for use in various experimental, diagnostic or therapeutic uses, including immunotherapy treatment or prophylaxy of tumors. More particularly, the present invention relates to methods of preparing membrane vesicles (in particular exosomes) released by various types of mammalian cells, comprising diafiltration and/or density cushion centrifugation. The invention also provides novel methods for characterizing and analyzing exosome preparations, which can be used in quality control assay for the purpose of pharmaceutical product production. The invention is suitable to produce pharmaceutical grade preparations of such membrane vesicles and to fully characterize said preparations, for use in human beings.
    Type: Application
    Filed: February 9, 2001
    Publication date: December 2, 2004
    Applicant: AP CELLS. INC.
    Inventors: Henry Lamparski, Curtis Ruegg, Jean-Bernard Le-Pecq, Di-Hewi Hsu, Jenq-Yuan Yao
  • Patent number: 6812023
    Abstract: The present invention relates to methods of preparing biological material, for use in various experimental, diagnostic or therapeutic uses, including immunotherapy treatment or prophylaxy of tumors. More particularly, the present invention relates to methods of preparing membrane vesicles (in particular exosomes) released by various types of mammalian cells, comprising diafiltration and/or density cushion centrifugation. The invention also provides novel methods for characterizing and analyzing exosome preparations, which can be used in quality control assay for the purpose of pharmaceutical product production. The invention is suitable to produce pharmaceutical grade preparations of such membrane vesicles and to fully characterize said preparations, for use in human beings.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: November 2, 2004
    Assignee: Anosys, Inc.
    Inventors: Henry Lamparski, Curtis Ruegg, Jean-Bernard Le Pecq, Di-Hewi Hsu, Jenq Yuan Yao
  • Patent number: 6585968
    Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: July 1, 2003
    Assignee: Cell Genesys, Inc.
    Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
  • Publication number: 20030026792
    Abstract: Replication-competent adenovirus vectors specific for cells expressing carcinoembryonic antigen (CEA), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a CEA transcriptional regulatory element (CEA-TRE). The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one other adenoviral gene under control of another transcriptional regulatory element specific to cells capable of which allow a CEA-TRE to function, such as a variant of a CEA-TRE. By providing for transcriptional initiating regulation dependent upon CEA expression, virus replication can be restricted to target cells which allow a CEA-TRE to function, such as cells expressing CEA, particularly carcinoma cells capable of expressing CEA. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter gene under transcriptional control of a CEA-TRE.
    Type: Application
    Filed: October 23, 2001
    Publication date: February 6, 2003
    Inventors: Henry Lamparski, Eric R. Schuur, Daniel R. Henderson
  • Publication number: 20020164799
    Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Application
    Filed: July 2, 2001
    Publication date: November 7, 2002
    Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
  • Patent number: 6254862
    Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: July 3, 2001
    Assignee: Calydon, Inc.
    Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski